Glenn M. Chertow

Publications

• A transcriptional blueprint for human and murine diabetic kidney disease. Bhalla V, Velez MG, Chertow GM. Diabetes. 2013; 62 (1): 31-3
• Association of physical activity with survival among ambulatory patients on dialysis: the comprehensive dialysis study. Johansen KL, Kaysen GA, Dalrymple LS, Grimes BA, Glidden DV, Anand S, Chertow GM. Clin J Am Soc Nephrol. 2013; 8 (2): 248-53
• Cinacalcet for cardiovascular disease in patients undergoing dialysis. Chertow GM, Parfrey PS. N Engl J Med. 2013; 368 (19): 1844-5
• Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. Erickson KF, Japa S, Owens DK, Chertow GM, Garber AM, Goldhaber-Fiebert JD. J Am Coll Cardiol. 2013; 61 (12): 1250-8
• Diabetic Severity and Risk of Kidney Stone Disease. Weinberg AE, Patel CJ, Chertow GM, Leppert JT. Eur Urol. 2013
• Effect of frequent hemodialysis on residual kidney function. Daugirdas JT, Greene T, Rocco MV, Kaysen GA, Depner TA, Levin NW, Chertow GM, Ornt DB, Raimann JG, Larive B, Kliger AS. Kidney Int. 2013; 83 (5): 949-58
• Effects of 6-Times-Weekly Versus 3-Times-Weekly Hemodialysis on Depressive Symptoms and Self-reported Mental Health: Frequent Hemodialysis Network (FHN) Trials. Unruh ML, Larive B, Chertow GM, Eggers PW, Garg AX, Gassman J, Tarallo M, Finkelstein FO, Kimmel PL. Am J Kidney Dis. 2013; 61 (5): 748-58
• Longitudinal measures of serum albumin and prealbumin concentrations in incident dialysis patients: the comprehensive dialysis study. Dalrymple LS, Johansen KL, Chertow GM, Grimes B, Anand S, McCulloch CE, Kaysen GA. J Ren Nutr. 2013; 23 (2): 91-7
• Physical activity and self-reported symptoms of insomnia, restless legs syndrome, and depression: the comprehensive dialysis study. Anand S, Johansen KL, Grimes B, Kaysen GA, Dalrymple LS, Kutner NG, Chertow GM. Hemodial Int. 2013; 17 (1): 50-8
• Prevention of Contrast-Induced AKI: A Review of Published Trials and the Design of the Prevention of Serious Adverse Events following Angiography (PRESERVE) Trial. Weisbord SD, Gallagher M, Kaufman J, Cass A, Parikh CR, Chertow GM, Shunk KA, McCullough PA, Fine MJ, Mor MK, Lew RA, Huang GD, Conner TA, Brophy MT, Lee J, Soliva S, Palevsky PM. Clin J Am Soc Nephrol. 2013
• Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM. Am J Nephrol. 2013; 37 (3): 212-22
• Risk factors of short-term mortality after acute nonvariceal upper gastrointestinal bleeding in patients on dialysis: a population-based study. Yang JY, Lee TC, Montez-Rath ME, Chertow GM, Winkelmayer WC. BMC Nephrol. 2013: 14 97
• Temporal Trends in the Incidence, Treatment, and Outcomes of Hip Fracture in Older Patients Initiating Dialysis in the United States. Nair SS, Mitani AA, Goldstein BA, Chertow GM, Lowenberg DW, Winkelmayer WC. Clin J Am Soc Nephrol. 2013
• Trends in acute kidney injury, associated use of dialysis, and mortality after cardiac surgery, 1999 to 2008. Lenihan CR, Montez-Rath ME, Mora Mangano CT, Chertow GM, Winkelmayer WC. Ann Thorac Surg. 2013; 95 (1): 20-8
• Variation in Nephrologist Visits to Patients on Hemodialysis across Dialysis Facilities and Geographic Locations. Erickson KF, Tan KB, Winkelmayer WC, Chertow GM, Bhattacharya J. Clin J Am Soc Nephrol. 2013
• Challenges to enrollment and randomization of the Frequent Hemodialysis Network (FHN) Daily Trial. Sergeyeva O, Gorodetskaya I, Ramos R, Schiller BM, Larive B, Raimann JG, Ting GO, Eggers PW, Chertow GM, Levin NW. J Nephrol. 2012 May-Jun; 25 (3): 302-9
• Acute kidney injury and mortality in hospitalized patients. Wang HE, Muntner P, Chertow GM, Warnock DG. Am J Nephrol. 2012; 35 (4): 349-55
• Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. Reisman SA, Chertow GM, Hebbar S, Vaziri ND, Ward KW, Meyer CJ. J Am Soc Nephrol. 2012; 23 (10): 1663-73
• Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Wheeler DC, Parfrey PS. Nephrol Dial Transplant. 2012; 27 (7): 2872-9
• Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings. Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA. Clin J Am Soc Nephrol. 2012; 7 (5): 856-60
• Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials. Okusa MD, Molitoris BA, Palevsky PM, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Faubel S, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA. Clin J Am Soc Nephrol. 2012; 7 (5): 851-5
• Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA. Clin J Am Soc Nephrol. 2012; 7 (5): 844-50
• Determinants of left ventricular mass in patients on hemodialysis: Frequent Hemodialysis Network (FHN) Trials. Chan CT, Greene T, Chertow GM, Kliger AS, Stokes JB, Beck GJ, Daugirdas JT, Kotanko P, Larive B, Levin NW, Mehta RL, Rocco M, Sanz J, Schiller BM, Yang PC, Rajagopalan S. Circ Cardiovasc Imaging. 2012; 5 (2): 251-61
• Donor-recipient sex mismatch in kidney transplantation. Tan JC, Kim JP, Chertow GM, Grumet FC, Desai M. Gend Med. 2012; 9 (5): 335-347.e2
• Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. Daugirdas JT, Chertow GM, Larive B, Pierratos A, Greene T, Ayus JC, Kendrick CA, James SH, Miller BW, Schulman G, Salusky IB, Kliger AS. J Am Soc Nephrol. 2012; 23 (4): 727-38
• Effects of phosphate binders in moderate CKD. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. J Am Soc Nephrol. 2012; 23 (8): 1407-15
• Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials. Hall YN, Larive B, Painter P, Kaysen GA, Lindsay RM, Nissenson AR, Unruh ML, Rocco MV, Chertow GM. Clin J Am Soc Nephrol. 2012; 7 (5): 782-94
• Frailty, dialysis initiation, and mortality in end-stage renal disease. Bao Y, Dalrymple L, Chertow GM, Kaysen GA, Johansen KL. Arch Intern Med. 2012; 172 (14): 1071-7
• Homelessness and CKD: a cohort study. Hall YN, Choi AI, Himmelfarb J, Chertow GM, Bindman AB. Clin J Am Soc Nephrol. 2012; 7 (7): 1094-102
• Individualized reduction in dialysate sodium in conventional in-center hemodialysis. Arramreddy R, Sun SJ, Munoz Mendoza J, Chertow GM, Schiller B. Hemodial Int. 2012; 16 (4): 473-80
• Ongoing clinical trials in AKI. Faubel S, Chawla LS, Chertow GM, Goldstein SL, Jaber BL, Liu KD. Clin J Am Soc Nephrol. 2012; 7 (5): 861-73
• Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis. Warnock DG, Hebbar S, Bargman J, Burkart J, Davies S, Finkelstein FO, Mehrotra R, Ronco C, Teitelbaum I, Urakpo K, Chertow GM. Contrib Nephrol. 2012: 178 157-63
• Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Chertow GM, Lu ZJ, Xu X, Knight TG, Goodman WG, Bushinsky DA, Block GA. Hemodial Int. 2012; 16 (2): 188-97
• The effect of frequent hemodialysis on nutrition and body composition: frequent Hemodialysis Network Trial. Kaysen GA, Greene T, Larive B, Mehta RL, Lindsay RM, Depner TA, Hall YN, Daugirdas JT, Chertow GM. Kidney Int. 2012; 82 (1): 90-9
• Toward the optimal dose metric in continuous renal replacement therapy. Claure-Del Granado R, Macedo E, Chertow GM, Soroko S, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL. Int J Artif Organs. 2012; 35 (6): 413-24
• Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. Yang JY, Lee TC, Montez-Rath ME, Paik J, Chertow GM, Desai M, Winkelmayer WC. J Am Soc Nephrol. 2012; 23 (3): 495-506
• Validation of reported predialysis nephrology care of older patients initiating dialysis. Kim JP, Desai M, Chertow GM, Winkelmayer WC. J Am Soc Nephrol. 2012; 23 (6): 1078-85
• Venous thromboembolism: yet another cardiovascular complication of chronic kidney disease? Chertow GM, Mahaffey KW. Circulation. 2012; 126 (16): 1937-8
• Living donor evaluation and exclusion: the Stanford experience. Lapasia JB, Kong SY, Busque S, Scandling JD, Chertow GM, Tan JC. Clin Transplant. 2011 Sep-Oct; 25 (5): 697-704
• Assessment and management of vascular disease risk in patients with chronic kidney disease. Brown WV, Bakris G, Lerma E, Chertow G. J Clin Lipidol. 2011 Jul-Aug; 5 (4): 251-60
• The phosphate binder equivalent dose. Daugirdas JT, Finn WF, Emmett M, Chertow GM. Semin Dial. 2011 Jan-Feb; 24 (1): 41-9
• Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Chang TI, Shilane D, Brunelli SM, Cheung AK, Chertow GM, Winkelmayer WC. Am Heart J. 2011; 162 (2): 324-30
• Aspirin and arteriovenous graft thrombosis in hemodialysis: just what the doctor ordered? Bech FR, Chertow GM. J Am Soc Nephrol. 2011; 22 (4): 595-7
• Association of self-reported physical activity with laboratory markers of nutrition and inflammation: the Comprehensive Dialysis Study. Anand S, Chertow GM, Johansen KL, Grimes B, Kurella Tamura M, Dalrymple LS, Kaysen GA. J Ren Nutr. 2011; 21 (6): 429-37
• Baseline characteristics of participants in the Frequent Hemodialysis Network (FHN) daily and nocturnal trials. Rocco MV, Larive B, Eggers PW, Beck GJ, Chertow GM, Levin NW, Kliger AS. Am J Kidney Dis. 2011; 57 (1): 90-100
• Baseline physical performance, health, and functioning of participants in the Frequent Hemodialysis Network (FHN) trial. Kaysen GA, Larive B, Painter P, Craig A, Lindsay RM, Rocco MV, Daugirdas JT, Schulman G, Chertow GM. Am J Kidney Dis. 2011; 57 (1): 101-12
• Burden on caregivers as perceived by hemodialysis patients in the Frequent Hemodialysis Network (FHN) trials. Suri RS, Larive B, Garg AX, Hall YN, Pierratos A, Chertow GM, Gorodetskeya I, Kliger AS. Nephrol Dial Transplant. 2011; 26 (7): 2316-22
• Chronic kidney disease and cardiovascular therapeutics: time to close the evidence gaps. Chang TI, Chertow GM. J Am Coll Cardiol. 2011; 58 (11): 1162-4
• Dialysate sodium and sodium gradient in maintenance hemodialysis: a neglected sodium restriction approach? Munoz Mendoza J, Sun S, Chertow GM, Moran J, Doss S, Schiller B. Nephrol Dial Transplant. 2011; 26 (4): 1281-7
• Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis. Claure-Del Granado R, Macedo E, Chertow GM, Soroko S, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL. Clin J Am Soc Nephrol. 2011; 6 (3): 467-75
• Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure. Haddad F, Fuh E, Peterson T, Skhiri M, Kudelko KT, De Jesus Perez V, Winkelmayer WC, Doyle RL, Chertow GM, Zamanian RT. J Card Fail. 2011; 17 (7): 533-9
• Intradialytic hypotension and vascular access thrombosis. Chang TI, Paik J, Greene T, Desai M, Bech F, Cheung AK, Chertow GM. J Am Soc Nephrol. 2011; 22 (8): 1526-33
• Model to predict mortality in critically ill adults with acute kidney injury. Demirjian S, Chertow GM, Zhang JH, O'Connor TZ, Vitale J, Paganini EP, Palevsky PM. Clin J Am Soc Nephrol. 2011; 6 (9): 2114-20
• Modeled urea distribution volume and mortality in the HEMO Study. Daugirdas JT, Greene T, Depner TA, Levin NW, Chertow GM. Clin J Am Soc Nephrol. 2011; 6 (5): 1129-38
• Predialysis nephrology care of older patients approaching end-stage renal disease. Winkelmayer WC, Liu J, Chertow GM, Tamura MK. Arch Intern Med. 2011; 171 (15): 1371-8
• Racial ethnic differences in rates and determinants of deceased donor kidney transplantation. Hall YN, Choi AI, Xu P, O'Hare AM, Chertow GM. J Am Soc Nephrol. 2011; 22 (4): 743-51
• Relationship of body size and mortality among US Asians and Pacific Islanders on dialysis. Hall YN, Xu P, Chertow GM. Ethn Dis. 2011; 21 (1): 40-6
• Risk of cardiovascular events after infection-related hospitalizations in older patients on dialysis. Dalrymple LS, Mohammed SM, Mu Y, Johansen KL, Chertow GM, Grimes B, Kaysen GA, Nguyen DV. Clin J Am Soc Nephrol. 2011; 6 (7): 1708-13
• Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. Mehta RL, Bouchard J, Soroko SB, Ikizler TA, Paganini EP, Chertow GM, Himmelfarb J. Intensive Care Med. 2011; 37 (2): 241-8
• Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. Chang TI, Friedman GD, Cheung AK, Greene T, Desai M, Chertow GM. J Hum Hypertens. 2011; 25 (2): 98-105
• The 2011 ESRD prospective payment system: an uncontrolled experiment. Winkelmayer WC, Chertow GM. Am J Kidney Dis. 2011; 57 (4): 542-6
• The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J. Nephrol Dial Transplant. 2011; 26 (4): 1327-39
• The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Rocco MV, Lockridge RS, Beck GJ, Eggers PW, Gassman JJ, Greene T, Larive B, Chan CT, Chertow GM, Copland M, Hoy CD, Lindsay RM, Levin NW, Ornt DB, Pierratos A, Pipkin MF, Rajagopalan S, Stokes JB, Unruh ML, Star RA, Kliger AS, Kliger A, Eggers P, Briggs J, Hostetter T, Narva A, Star R, Augustine B, Mohr P, Beck G, Fu Z, Gassman J, Greene T, Daugirdas J, Hunsicker L, Larive B, Li M, Mackrell J, Wiggins K, Sherer S, Weiss B, Rajagopalan S, Sanz J, Dellagrottaglie S, Kariisa M, Tran T, West J, Unruh M, Keene R, Schlarb J, Chan C, McGrath-Chong M, Frome R, Higgins H, Ke S, Mandaci O, Owens C, Snell C, Eknoyan G, Appel L, Cheung A, Derse A, Kramer C, Geller N, Grimm R, Henderson L, Prichard S, Roecker E, Rocco M, Miller B, Riley J, Schuessler R, Lockridge R, Pipkin M, Peterson C, Hoy C, Fensterer A, Steigerwald D, Stokes J, Somers D, Hilkin A, Lilli K, Wallace W, Franzwa B, Waterman E, Chan C, McGrath-Chong M, Copland M, Levin A, Sioson L, Cabezon E, Kwan S, Roger D, Lindsay R, Suri R, Champagne J, Bullas R, Garg A, Mazzorato A, Spanner E, Rocco M, Burkart J, Moossavi S, Mauck V, Kaufman T, Pierratos A, Chan W, Regozo K, Kwok S. Kidney Int. 2011; 80 (10): 1080-91
• Update in nephrology: evidence published in 2010. Arora N, Chertow GM. Ann Intern Med. 2011; 154 (12): 824-9, W-299
• Validity of surrogate measures for functional nephron mass. Tan JC, Paik J, Chertow GM, Grumet FC, Busque S, Lapasia J, Desai M. Transplantation. 2011; 92 (12): 1335-41
• Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study. Kurella Tamura M, Xie D, Yaffe K, Cohen DL, Teal V, Kasner SE, Messé SR, Sehgal AR, Kusek J, DeSalvo KB, Cornish-Zirker D, Cohan J, Seliger SL, Chertow GM, Go AS. Clin J Am Soc Nephrol. 2011; 6 (2): 248-56
• Vitamin D deficiency, self-reported physical activity and health-related quality of life: the Comprehensive Dialysis Study. Anand S, Kaysen GA, Chertow GM, Johansen KL, Grimes B, Dalrymple LS, Kurella Tamura M. Nephrol Dial Transplant. 2011; 26 (11): 3683-8
• World Kidney Day 2011. Hostetter TH, Kochis DJ, Shaffer RN, Chertow G, Harmon WE, Klotman PE, Powe NR, Sedor JR, Smedberg PC, Watnick S, Winkelmayer WC. J Am Soc Nephrol. 2011; 22 (3): 397-8
• Effects of reduced intradialytic urea generation rate and residual renal clearance on modeled urea distribution volume and Kt/V in conventional, daily, and nocturnal dialysis. Daugirdas JT, Depner TA, Greene T, Levin NW, Chertow GM, Rocco MV, Stokes JB. Semin Dial. 2010 Jan-Feb; 23 (1): 19-24
• Blood pressure control in type 2 diabetes mellitus. Chang TI, Cheung AK, Chertow GM. Am J Kidney Dis. 2010; 56 (6): 1029-31
• Can rescaling dose of dialysis to body surface area in the HEMO study explain the different responses to dose in women versus men? Daugirdas JT, Greene T, Chertow GM, Depner TA. Clin J Am Soc Nephrol. 2010; 5 (9): 1628-36
• Chronic kidney disease in the urban poor. Hall YN, Choi AI, Chertow GM, Bindman AB. Clin J Am Soc Nephrol. 2010; 5 (5): 828-35
• Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury. Bouchard J, Macedo E, Soroko S, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL. Nephrol Dial Transplant. 2010; 25 (1): 102-7
• Curbing the use of ultrasonography in the diagnosis of acute kidney injury: Penny wise or pound foolish?: Comment on "Renal ultrasonography in the evaluation of acute kidney injury". Liu KD, Chertow GM. Arch Intern Med. 2010; 170 (21): 1907-8
• Determinants of cardiac autonomic dysfunction in ESRD. Chan CT, Levin NW, Chertow GM, Larive B, Schulman G, Kotanko P. Clin J Am Soc Nephrol. 2010; 5 (10): 1821-7
• End-stage Renal Disease. Abbasi M, Chertow G, Hall Y. Am Fam Physician. 2010; 82 (12): 1512
• End-stage renal disease. Abbasi MA, Chertow GM, Hall YN. Clin Evid (Online). 2010 2010
• Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. Macedo E, Bouchard J, Soroko SH, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL. Crit Care. 2010; 14 (3): R82
• GFR estimating equations, CKD prevalence and the public health. Chang TI, Chertow GM. J Intern Med. 2010; 267 (4): 354-6
• In-center hemodialysis six times per week versus three times per week. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS. N Engl J Med. 2010; 363 (24): 2287-300
• Infection-related hospitalizations in older patients with ESRD. Dalrymple LS, Johansen KL, Chertow GM, Cheng SC, Grimes B, Gold EB, Kaysen GA. Am J Kidney Dis. 2010; 56 (3): 522-30
• Kidney disease, hospitalized hypertension, and cardiovascular events: cause or consequence? Chertow GM, Chang TI. Circulation. 2010; 121 (20): 2160-1
• Low level of self-reported physical activity in ambulatory patients new to dialysis. Johansen KL, Chertow GM, Kutner NG, Dalrymple LS, Grimes BA, Kaysen GA. Kidney Int. 2010; 78 (11): 1164-70
• Off-label use of phosphate binders in non-dialysis-dependent CKD. Winkelmayer WC, Chertow GM. Am J Kidney Dis. 2010; 56 (5): 813-6
• On the relative safety of intravenous iron formulations: new answers, new questions. Chertow GM, Winkelmayer WC. Am J Hematol. 2010; 85 (9): 643-4
• Prevalence and correlates of cognitive impairment in hemodialysis patients: the Frequent Hemodialysis Network trials. Kurella Tamura M, Larive B, Unruh ML, Stokes JB, Nissenson A, Mehta RL, Chertow GM. Clin J Am Soc Nephrol. 2010; 5 (8): 1429-38
• Projected effect of dietary salt reductions on future cardiovascular disease. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L. N Engl J Med. 2010; 362 (7): 590-9
• Reexploring differences among for-profit and nonprofit dialysis providers. Lee DK, Chertow GM, Zenios SA. Health Serv Res. 2010; 45 (3): 633-46
• Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Brunelli SM, Chertow GM, Ankers ED, Lowrie EG, Thadhani R. Kidney Int. 2010; 77 (7): 630-6
• Standard Kt/Vurea: a method of calculation that includes effects of fluid removal and residual kidney clearance. Daugirdas JT, Depner TA, Greene T, Levin NW, Chertow GM, Rocco MV. Kidney Int. 2010; 77 (7): 637-44
• Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Chertow GM. Nephrol Dial Transplant. 2010; 25 (6): 1916-23
• The authors reply:. Brunelli SM, Chertow GM, Ankers ED, Lowrie EG, Thadhani R. Kidney Int. 2010; 78 (7): 710-1
• The elderly patients on hemodialysis. Anand S, Kurella Tamura M, Chertow GM. Minerva Urol Nefrol. 2010; 62 (1): 87-101
• Updated comorbidity assessments and outcomes in prevalent hemodialysis patients. Chang TI, Paik J, Greene T, Miskulin DC, Chertow GM. Hemodial Int. 2010; 14 (4): 478-85
• Vitamin D deficiency and frailty in older Americans. Wilhelm-Leen ER, Hall YN, Deboer IH, Chertow GM. J Intern Med. 2010; 268 (2): 171-80
• Weekend hospital admission, acute kidney injury, and mortality. James MT, Wald R, Bell CM, Tonelli M, Hemmelgarn BR, Waikar SS, Chertow GM. J Am Soc Nephrol. 2010; 21 (5): 845-51
• Increased fluid intake does not augment capacity to lay down new collagen in nursing home residents at risk for pressure ulcers: a randomized, controlled clinical trial. Stotts NA, Hopf HW, Kayser-Jones J, Chertow GM, Cooper BA, Wu HS. Wound Repair Regen. 2009 Nov-Dec; 17 (6): 780-8
• An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Lee CP, Chertow GM, Zenios SA. Value Health. 2009 Jan-Feb; 12 (1): 80-7
• A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Block GA, Persky MS, Ketteler M, Kestenbaum B, Thadhani R, Kooienga L, Spiegel D, Asplin J, Ehrlich J, Dennis V, Nissenson A, Chertow GM, Wheeler DC. Hemodial Int. 2009; 13 (3): 360-2
• Cautious optimism concerning long-term safety of kidney donation. Tan JC, Chertow GM. N Engl J Med. 2009; 360 (5): 522-3
• Characteristics of uninsured Americans with chronic kidney disease. Hall YN, Rodriguez RA, Boyko EJ, Chertow GM, O'Hare AM. J Gen Intern Med. 2009; 24 (8): 917-22
• Choroidopathy and kidney disease: a case report and review of the literature. Kamdar NV, Erko A, Ehrlich JS, Kim JW, Kambham N, Chertow GM. Cases J. 2009: 2 7425
• Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordoñez JD, Hsu CY. Kidney Int. 2009; 76 (8): 893-9
• Dialysis: Phosphorus binders and survival: need for randomized trials. Ix JH, Chertow GM. Nat Rev Nephrol. 2009; 5 (7): 368-70
• Fetuin-A and change in body composition in older persons. Ix JH, Wassel CL, Chertow GM, Koster A, Johnson KC, Tylavsky FA, Cauley JA, Cummings SR, Harris TB, Shlipak MG. J Clin Endocrinol Metab. 2009; 94 (11): 4492-8
• Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL. Kidney Int. 2009; 76 (4): 422-7
• Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. Wilhelm-Leen ER, Hall YN, K Tamura M, Chertow GM. Am J Med. 2009; 122 (7): 664-71.e2
• Functional status of elderly adults before and after initiation of dialysis. Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, McCulloch CE. N Engl J Med. 2009; 361 (16): 1539-47
• Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Palevsky PM, O'Connor TZ, Chertow GM, Crowley ST, Zhang JH, Kellum JA. Crit Care. 2009; 13 (4): 310
• Medication errors in chronic kidney disease: one piece in the patient safety puzzle. Fink JC, Chertow GM. Kidney Int. 2009; 76 (11): 1123-5
• Melamine nephrotoxicity: an emerging epidemic in an era of globalization. Bhalla V, Grimm PC, Chertow GM, Pao AC. Kidney Int. 2009; 75 (8): 774-9
• Preexisting chronic kidney disease: a potential for improved outcomes from acute kidney injury. Khosla N, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini E, Mehta RL. Clin J Am Soc Nephrol. 2009; 4 (12): 1914-9
• Regional variation in kidney transplant outcomes: trends over time. Chakkera HA, Chertow GM, O'Hare AM, Amend WJ, Gonwa TA. Clin J Am Soc Nephrol. 2009; 4 (1): 152-9
• The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: a systematic review. Desai AA, Nissenson A, Chertow GM, Farid M, Singh I, Van Oijen MG, Esrailian E, Solomon MD, Spiegel BM. Hemodial Int. 2009; 13 (3): 347-59
• Comparison of proposed alternative methods for rescaling dialysis dose: resting energy expenditure, high metabolic rate organ mass, liver size, and body surface area. Daugirdas JT, Levin NW, Kotanko P, Depner TA, Kuhlmann MK, Chertow GM, Rocco MV. Semin Dial. 2008 Sep-Oct; 21 (5): 377-84
• Surface-area-normalized Kt/V: a method of rescaling dialysis dose to body surface area-implications for different-size patients by gender. Daugirdas JT, Depner TA, Greene T, Kuhlmann MK, Levin NW, Chertow GM, Rocco MV. Semin Dial. 2008 Sep-Oct; 21 (5): 415-21
• A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Xie D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, Greene T, Hsu CY, Kusek JW, Landis R, Lash J, Levey AS, O'Conner A, Ojo A, Rahman M, Townsend RR, Wang H, Feldman HI. Clin J Am Soc Nephrol. 2008; 3 (5): 1332-8
• Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA. Nephrol Dial Transplant. 2008; 23 (7): 2311-8
• Cost-effectiveness of frequent in-center hemodialysis. Lee CP, Zenios SA, Chertow GM. J Am Soc Nephrol. 2008; 19 (9): 1792-7
• Diagnosis, epidemiology and outcomes of acute kidney injury. Waikar SS, Liu KD, Chertow GM. Clin J Am Soc Nephrol. 2008; 3 (3): 844-61
• High-molecular weight iron dextran: a wolf in sheep's clothing? Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy JA, Henry DH. J Am Soc Nephrol. 2008; 19 (5): 833-4
• Higher serum creatinine concentrations in black patients with chronic kidney disease: beyond nutritional status and body composition. Hsu J, Johansen KL, Hsu CY, Kaysen GA, Chertow GM. Clin J Am Soc Nephrol. 2008; 3 (4): 992-7
• Intensity of renal support in critically ill patients with acute kidney injury. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P. N Engl J Med. 2008; 359 (1): 7-20
• Kidney dysfunction and fatal cardiovascular disease--an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Deo R, Fyr CL, Fried LF, Newman AB, Harris TB, Angleman S, Green C, Kritchevsky SB, Chertow GM, Cummings SR, Shlipak MG. Am Heart J. 2008; 155 (1): 62-8
• Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Crowley ST, Chertow GM, Vitale J, O'Connor T, Zhang J, Schein RM, Choudhury D, Finkel K, Vijayan A, Paganini E, Palevsky PM. Clin J Am Soc Nephrol. 2008; 3 (4): 955-61
• Management of acute kidney injury in the intensive care unit: a cost-effectiveness analysis of daily vs alternate-day hemodialysis. Desai AA, Baras J, Berk BB, Nakajima A, Garber AM, Owens D, Chertow GM. Arch Intern Med. 2008; 168 (16): 1761-7
• Neighborhood poverty and kidney transplantation among US Asians and Pacific Islanders with end-stage renal disease. Hall YN, O'Hare AM, Young BA, Boyko EJ, Chertow GM. Am J Transplant. 2008; 8 (11): 2402-9
• The risk of acute renal failure in patients with chronic kidney disease. Hsu CY, Ordoñez JD, Chertow GM, Fan D, McCulloch CE, Go AS. Kidney Int. 2008; 74 (1): 101-7
• Toward the promise of renal replacement therapy. Chertow GM, Waikar SS. J Am Soc Nephrol. 2008; 19 (5): 839-40
• Trends and outcomes associated with serum albumin concentration among incident dialysis patients in the United States. Kaysen GA, Johansen KL, Cheng SC, Jin C, Chertow GM. J Ren Nutr. 2008; 18 (4): 323-31
• Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Circulation. 2007; 115 (2): 173-9
• Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Circulation. 2007; 115 (19): 2533-9
• Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients. Johansen KL, Chertow GM. J Ren Nutr. 2007; 17 (5): 305-13
• Community-based incidence of acute renal failure. Hsu CY, McCulloch CE, Fan D, Ordoñez JD, Chertow GM, Go AS. Kidney Int. 2007; 72 (2): 208-12
• End stage renal disease. Hall YN, Chertow GM. Clin Evid (Online). 2007 2007
• Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P. Clin J Am Soc Nephrol. 2007; 2 (5): 898-905
• Frequent Hemodialysis Network (FHN) randomized trials: study design. Suri RS, Garg AX, Chertow GM, Levin NW, Rocco MV, Greene T, Beck GJ, Gassman JJ, Eggers PW, Star RA, Ornt DB, Kliger AS. Kidney Int. 2007; 71 (4): 349-59
• Kidney function as a predictor of loss of lean mass in older adults: health, aging and body composition study. Fried LF, Boudreau R, Lee JS, Chertow G, Kurella-Tamura M, Shlipak MG, Ding J, Sellmeyer D, Tylavsky FA, Simsonick E, Kritchevsky SB, Harris TB, Newman AB. J Am Geriatr Soc. 2007; 55 (10): 1578-84
• Octogenarians and nonagenarians starting dialysis in the United States. Kurella M, Covinsky KE, Collins AJ, Chertow GM. Ann Intern Med. 2007; 146 (3): 177-83
• Phosphorus balance and mineral metabolism with 3 h daily hemodialysis. Ayus JC, Achinger SG, Mizani MR, Chertow GM, Furmaga W, Lee S, Rodriguez F. Kidney Int. 2007; 71 (4): 336-42
• Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Liu KD, Glidden DV, Eisner MD, Parsons PE, Ware LB, Wheeler A, Korpak A, Thompson BT, Chertow GM, Matthay MA. Crit Care Med. 2007; 35 (12): 2755-61
• Race and mortality after acute renal failure. Waikar SS, Curhan GC, Ayanian JZ, Chertow GM. J Am Soc Nephrol. 2007; 18 (10): 2740-8
• Rise of pay for performance: implications for care of people with chronic kidney disease. Desai AA, Garber AM, Chertow GM. Clin J Am Soc Nephrol. 2007; 2 (5): 1087-95
• Significance of frailty among dialysis patients. Johansen KL, Chertow GM, Jin C, Kutner NG. J Am Soc Nephrol. 2007; 18 (11): 2960-7
• The incidence and prognostic significance of acute kidney injury. Waikar SS, Liu KD, Chertow GM. Curr Opin Nephrol Hypertens. 2007; 16 (3): 227-36
• A simulation model to estimate the cost and effectiveness of alternative dialysis initiation strategies. Lee CP, Chertow GM, Zenios SA. Med Decis Making. 2006 Sep-Oct; 26 (5): 535-49
• Acute renal failure after endovascular vs open repair of abdominal aortic aneurysm. Wald R, Waikar SS, Liangos O, Pereira BJ, Chertow GM, Jaber BL. J Vasc Surg. 2006; 43 (3): 460-466; discussion 466
• Association of body size with health status in patients beginning dialysis. Johansen KL, Kutner NG, Young B, Chertow GM. Am J Clin Nutr. 2006; 83 (3): 543-9
• Challenging the validity of the EPO index. Kaysen GA, Müller HG, Ding J, Chertow GM. Am J Kidney Dis. 2006; 47 (1): 166
• Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J. Clin J Am Soc Nephrol. 2006; 1 (2): 305-12
• Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Kurella M, Mapes DL, Port FK, Chertow GM. Nephrol Dial Transplant. 2006; 21 (9): 2543-8
• Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. Odden MC, Chertow GM, Fried LF, Newman AB, Connelly S, Angleman S, Harris TB, Simonsick EM, Shlipak MG. Am J Epidemiol. 2006; 164 (12): 1180-9
• Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF. J Am Soc Nephrol. 2006; 17 (1): 254-61
• Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. J Card Fail. 2006; 12 (8): 601-7
• Declining mortality in patients with acute renal failure, 1988 to 2002. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. J Am Soc Nephrol. 2006; 17 (4): 1143-50
• End stage renal disease. Hall YN, Chertow GM. Clin Evid. 2006; (15): 1171-81
• Evolving practices in critical care and potential implications for management of acute kidney injury. Liu KD, Matthay MA, Chertow GM. Clin J Am Soc Nephrol. 2006; 1 (4): 869-73
• Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Nephrol Dial Transplant. 2006; 21 (8): 2144-51
• Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified. Ix JH, Quarles LD, Chertow GM. Nat Clin Pract Nephrol. 2006; 2 (6): 337-9
• Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation. Triponez F, Kebebew E, Dosseh D, Duh QY, Hazzan M, Noel C, Chertow GM, Wambergue F, Fleury D, Lemaitre V, Proye CA, Clark OH. Surgery. 2006; 140 (6): 990-7; discussion 997-9
• Lessons for Medicare Part D in the hemodialysis community. Nayeem AI, Chertow GM. BMC Nephrol. 2006: 7 11
• Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Chertow GM, Soroko SH, Paganini EP, Cho KC, Himmelfarb J, Ikizler TA, Mehta RL. Kidney Int. 2006; 70 (6): 1120-6
• PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. Am J Kidney Dis. 2006; 47 (1): 149-56
• Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Bibbins-Domingo K, Chertow GM, Fried LF, Odden MC, Newman AB, Kritchevsky SB, Harris TB, Satterfield S, Cummings SR, Shlipak MG. Arch Intern Med. 2006; 166 (13): 1396-402
• Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. Peralta CA, Shlipak MG, Fan D, Ordoñez J, Lash JP, Chertow GM, Go AS. J Am Soc Nephrol. 2006; 17 (10): 2892-9
• Strategies for successful patient oriented research: why did I (not) get funded? Agarwal R, Chertow GM, Mehta RL. Clin J Am Soc Nephrol. 2006; 1 (2): 340-3
• Studying the prevention of acute kidney injury: lessons from an 18th-century mathematician. Chertow GM, Palevsky PM, Greene T. Clin J Am Soc Nephrol. 2006; 1 (5): 1124-7
• Survival by dialysis modality in critically ill patients with acute kidney injury. Cho KC, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, Chertow GM. J Am Soc Nephrol. 2006; 17 (11): 3132-8
• Tesio catheter access for long-term maintenance hemodialysis. Wang J, LaBerge JM, Chertow GM, Kerlan RK, Wilson MW, Gordon RL. Radiology. 2006; 241 (1): 284-90
• The case against calcium-based phosphate binders. Moe SM, Chertow GM. Clin J Am Soc Nephrol. 2006; 1 (4): 697-703
• The enlarging body of evidence: obesity and chronic kidney disease. Chertow GM, Hsu CY, Johansen KL. J Am Soc Nephrol. 2006; 17 (6): 1501-2
• The metabolic syndrome and chronic kidney disease. Peralta CA, Kurella M, Lo JC, Chertow GM. Curr Opin Nephrol Hypertens. 2006; 15 (4): 361-5
• The tortoise and hare on hemodialysis: does slow and steady win the race? Chertow GM, Kurella M, Lowrie EG. Kidney Int. 2006; 70 (1): 24-5
• Timing of initiation of dialysis in critically ill patients with acute kidney injury. Liu KD, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, Chertow GM. Clin J Am Soc Nephrol. 2006; 1 (5): 915-9
• Update on adverse drug events associated with parenteral iron. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Nephrol Dial Transplant. 2006; 21 (2): 378-82
• Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. Waikar SS, Wald R, Chertow GM, Curhan GC, Winkelmayer WC, Liangos O, Sosa MA, Jaber BL. J Am Soc Nephrol. 2006; 17 (6): 1688-94
• Frequent hemodialysis and psychosocial function. Kurella M, Suri RS, Chertow GM. Semin Dial. 2005 Mar-Apr; 18 (2): 132-6
• Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Garg JP, Ellis R, Elliott WJ, Hasabou N, Chua D, Chertow GM, Bakris GL. Am J Nephrol. 2005 Jul-Aug; 25 (4): 393-9
• Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Kidney Int. 2005; 67 (2): 760-71
• Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. J Am Soc Nephrol. 2005; 16 (11): 3365-70
• Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Dwyer JT, Larive B, Leung J, Rocco MV, Greene T, Burrowes J, Chertow GM, Cockram DB, Chumlea WC, Daugirdas J, Frydrych A, Kusek JW. Kidney Int. 2005; 68 (4): 1766-76
• Beyond Framingham: cardiovascular risk profiling in ESRD. McClellan WM, Chertow GM. J Am Soc Nephrol. 2005; 16 (6): 1539-41
• Bone disease and bottle caps. Tichy M, Garg JP, Cho KC, Chertow GM. J Ren Nutr. 2005; 15 (2): 257-9
• Calcification or classification? Chertow GM, Moe SM. J Am Soc Nephrol. 2005; 16 (2): 293-5
• Chronic kidney disease and cognitive impairment in menopausal women. Kurella M, Yaffe K, Shlipak MG, Wenger NK, Chertow GM. Am J Kidney Dis. 2005; 45 (1): 66-76
• Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. Kurella M, Chertow GM, Fried LF, Cummings SR, Harris T, Simonsick E, Satterfield S, Ayonayon H, Yaffe K. J Am Soc Nephrol. 2005; 16 (7): 2127-33
• Control of hypertension in adults with chronic kidney disease in the United States. Peralta CA, Hicks LS, Chertow GM, Ayanian JZ, Vittinghoff E, Lin F, Shlipak MG. Hypertension. 2005; 45 (6): 1119-24
• Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM. J Bone Miner Res. 2005; 20 (5): 764-72
• Dialysis session length ("t") as a determinant of the adequacy of dialysis. Kurella M, Chertow GM. Semin Nephrol. 2005; 25 (2): 90-5
• Differential mortality and transplantation rates among Asians and Pacific Islanders with ESRD. Hall YN, Sugihara JG, Go AS, Chertow GM. J Am Soc Nephrol. 2005; 16 (12): 3711-20
• Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM. Arthritis Rheum. 2005; 52 (1): 290-5
• Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Kidney Int. 2005; 68 (4): 1793-800
• End stage renal disease. Hall Y, Chertow G. Clin Evid. 2005; (13): 1048-59
• Health-related quality of life and estimates of utility in chronic kidney disease. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, Go AS, Chertow GM. Kidney Int. 2005; 68 (6): 2801-8
• Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Lo JC, Chertow GM, Go AS, Hsu CY. Kidney Int. 2005; 67 (3): 1047-52
• Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs. Chakkera HA, O'Hare AM, Johansen KL, Hynes D, Stroupe K, Colin PM, Chertow GM. J Am Soc Nephrol. 2005; 16 (1): 269-77
• Insulin resistance in critically ill patients with acute renal failure. Basi S, Pupim LB, Simmons EM, Sezer MT, Shyr Y, Freedman S, Chertow GM, Mehta RL, Paganini E, Himmelfarb J, Ikizler TA. Am J Physiol Renal Physiol. 2005; 289 (2): F259-64
• Medicare ESRD prospective payment system: weighing the evidence. Himmelfarb J, Chertow GM. J Am Soc Nephrol. 2005; 16 (5): 1164-5
• Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. Kurella M, Lo JC, Chertow GM. J Am Soc Nephrol. 2005; 16 (7): 2134-40
• Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Am Heart J. 2005; 149 (5): 820-5
• Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. Chertow GM, Goldstein-Fuchs DJ, Lazarus JM, Kaysen GA. Kidney Int. 2005; 68 (6): 2794-800
• Self-assessed sleep quality in chronic kidney disease. Kurella M, Luan J, Lash JP, Chertow GM. Int Urol Nephrol. 2005; 37 (1): 159-65
• Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Burrowes JD, Larive B, Chertow GM, Cockram DB, Dwyer JT, Greene T, Kusek JW, Leung J, Rocco MV. Nephrol Dial Transplant. 2005; 20 (12): 2765-74
• Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. Kirtane AJ, Leder DM, Waikar SS, Chertow GM, Ray KK, Pinto DS, Karmpaliotis D, Burger AJ, Murphy SA, Cannon CP, Braunwald E, Gibson CM. J Am Coll Cardiol. 2005; 45 (11): 1781-6
• Suicide in the United States end-stage renal disease program. Kurella M, Kimmel PL, Young BS, Chertow GM. J Am Soc Nephrol. 2005; 16 (3): 774-81
• "Renalism": inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. Chertow GM, Normand SL, McNeil BJ. J Am Soc Nephrol. 2004; 15 (9): 2462-8
• A 43-year-old woman with chronic renal insufficiency. Chertow GM, JAMA. 2004; 291 (10): 1252-9
• Association of body size with outcomes among patients beginning dialysis. Johansen KL, Young B, Kaysen GA, Chertow GM. Am J Clin Nutr. 2004; 80 (2): 324-32
• Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. N Engl J Med. 2004; 351 (13): 1296-305
• Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moyé LA, Pfeffer MA, Solomon SD. Circulation. 2004; 110 (24): 3667-73
• Cognitive impairment in chronic kidney disease. Kurella M, Chertow GM, Luan J, Yaffe K. J Am Geriatr Soc. 2004; 52 (11): 1863-9
• Coronary and aortic calcifications in patients new to dialysis. Spiegel DM, Raggi P, Mehta R, Lindberg JS, Chonchol M, Ehrlich J, James G, Chertow GM, Block GA. Hemodial Int. 2004; 8 (3): 265-72
• Determinants of progressive vascular calcification in haemodialysis patients. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Nephrol Dial Transplant. 2004; 19 (6): 1489-96
• Diminishing significance of HLA matching in kidney transplantation. Su X, Zenios SA, Chakkera H, Milford EL, Chertow GM. Am J Transplant. 2004; 4 (9): 1501-8
• Incorporating recipient choice in kidney transplantation. Su X, Zenios SA, Chertow GM. J Am Soc Nephrol. 2004; 15 (6): 1656-63
• Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. J Am Soc Nephrol. 2004; 15 (8): 2208-18
• On the relative safety of parenteral iron formulations. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Nephrol Dial Transplant. 2004; 19 (6): 1571-5
• Physical and sexual function in women with chronic kidney disease. Kurella M, Ireland C, Hlatky MA, Shlipak MG, Yaffe K, Hulley SB, Chertow GM. Am J Kidney Dis. 2004; 43 (5): 868-76
• Plasma cytokine levels predict mortality in patients with acute renal failure. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA. Kidney Int. 2004; 65 (4): 1357-65
• Prevention of radiocontrast nephropathy: back to basics. Chertow GM, JAMA. 2004; 291 (19): 2376-7
• Race/ethnicity and disease severity in IgA nephropathy. Hall YN, Fuentes EF, Chertow GM, Olson JL. BMC Nephrol. 2004: 5 10
• Screening to prevent coronary events or screening to detect obstruction? Raggi P, Budoff MJ, Chertow GM. Am J Kidney Dis. 2004; 43 (5): 940; author reply 940-1
• Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM. Kidney Int. 2004; 66 (4): 1613-21
• The influence of patient- and facility-specific factors on nutritional status and survival in hemodialysis. Kaysen GA, Müller HG, Young BS, Leng X, Chertow GM. J Ren Nutr. 2004; 14 (2): 72-81
• Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Ix JH, McCulloch CE, Chertow GM. Nephrol Dial Transplant. 2004; 19 (11): 2747-53
• Validation of the Kidney Disease Quality of Life (KDQOL) cognitive function subscale. Kurella M, Luan J, Yaffe K, Chertow GM. Kidney Int. 2004; 66 (6): 2361-7
• Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. Raggi P, Bommer J, Chertow GM. J Heart Valve Dis. 2004; 13 (1): 134-41
• Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. Pillon L, Piccoli A, Lowrie EG, Lazarus JM, Chertow GM. Kidney Int. 2004; 66 (3): 1266-71
• The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. Am J Nephrol. 2003 Sep-Oct; 23 (5): 307-14
• Acute renal failure definitions and classification: time for change? Mehta RL, Chertow GM. J Am Soc Nephrol. 2003; 14 (8): 2178-87
• Analgesia in patients with ESRD: a review of available evidence. Kurella M, Bennett WM, Chertow GM. Am J Kidney Dis. 2003; 42 (2): 217-28
• Anthropometrically estimated total body water volumes are larger than modeled urea volume in chronic hemodialysis patients: effects of age, race, and gender. Daugirdas JT, Greene T, Depner TA, Chumlea C, Rocco MJ, Chertow GM. Kidney Int. 2003; 64 (3): 1108-19
• Beware the rising creatinine level. Shlipak MG, Chertow GC, Massie BM. J Card Fail. 2003; 9 (1): 26-8
• In critically ill patients with acute renal failure, outcomes, not dollars, should drive modality choice. Mehta RL, Chertow GM. Crit Care Med. 2003; 31 (2): 644-6
• Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. Hung AM, Chertow GM, Young BS, Carey S, Johansen KL. Adv Ren Replace Ther. 2003; 10 (3): 232-40
• Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. Johansen KL, Kaysen GA, Young BS, Hung AM, da Silva M, Chertow GM. Am J Clin Nutr. 2003; 77 (4): 842-6
• Reasons for non-enrollment in a cohort study of ARF: the Program to Improve Care in Acute Renal Disease (PICARD) experience and implications for a clinical trials network. Chertow GM, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL. Am J Kidney Dis. 2003; 42 (3): 507-12
• Slowing the progression of vascular calcification in hemodialysis. Chertow GM, J Am Soc Nephrol. 2003; 14 (9 Suppl 4): S310-4
• The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT. J Am Soc Nephrol. 2003; 14 (7 Suppl 2): S148-53
• The decline in residual renal function in hemodialysis is slow and age dependent. Hung AM, Young BS, Chertow GM. Hemodial Int. 2003; 7 (1): 17-22
• With bioimpedance spectroscopy, the errors get fat when the patients get slim. Chertow GM, JPEN J Parenter Enteral Nutr. 2002 Mar-Apr; 26 (2): 128-9
• Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Ann Intern Med. 2002; 137 (7): 555-62
• Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Hsu CY, Cummings SR, McCulloch CE, Chertow GM. Kidney Int. 2002; 61 (5): 1814-20
• Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. J Am Coll Cardiol. 2002; 39 (4): 695-701
• Diuretics, mortality, and nonrecovery of renal function in acute renal failure. Mehta RL, Pascual MT, Soroko S, Chertow GM. JAMA. 2002; 288 (20): 2547-53
• Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Hsu CY, Chertow GM. Nephrol Dial Transplant. 2002; 17 (8): 1419-25
• Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. Hung AM, Chertow GM, Young BS, Carey S, Johansen KL. J Ren Nutr. 2002; 12 (3): 170-6
• Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Hsu CY, Chertow GM, Curhan GC. Kidney Int. 2002; 61 (5): 1567-76
• Nephrology consultation in acute renal failure: does timing matter? Mehta RL, McDonald B, Gabbai F, Pahl M, Farkas A, Pascual MT, Zhuang S, Kaplan RM, Chertow GM. Am J Med. 2002; 113 (6): 456-61
• Refining predictive models in critically ill patients with acute renal failure. Mehta RL, Pascual MT, Gruta CG, Zhuang S, Chertow GM. J Am Soc Nephrol. 2002; 13 (5): 1350-7
• Renal insufficiency with monoclonal gammopathy and urticarial vasculitis. O'Hare A, Olson JL, Connolly MK, Ward JW, Stein P, Wisnieski JJ, Chertow GM. Am J Kidney Dis. 2002; 39 (1): 203-7
• Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Chertow GM, Burke SK, Raggi P. Kidney Int. 2002; 62 (1): 245-52
• The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. J Am Soc Nephrol. 2002; 13 (11): 2762-9
• "Wishing don't make it so"--why we need a randomized clinical trial of high-intensity hemodialysis. Chertow GM, J Am Soc Nephrol. 2001; 12 (12): 2850-3
• Cardiac arrest and sudden death in dialysis units. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, Chertow GM. Kidney Int. 2001; 60 (1): 350-7
• Correlates of acute renal failure in patients receiving parenteral amphotericin B. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Platt R. Kidney Int. 2001; 60 (4): 1452-9
• Determinants of physical performance in ambulatory patients on hemodialysis. Johansen KL, Chertow GM, da Silva M, Carey S, Painter P. Kidney Int. 2001; 60 (4): 1586-91
• Gridlock on the road to kidney transplantation. Chertow G, Zenios S. Am J Kidney Dis. 2001; 37 (2): 435-7
• Guided medication dosing for inpatients with renal insufficiency. Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, Seger DL, Lee R, Mekala A, Song J, Komaroff AL, Bates DW. JAMA. 2001; 286 (22): 2839-44
• Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW. Kidney Int. 2001; 60 (1): 333-40
• Mechanisms underlying renoprotection during renin-angiotensin system blockade. Taal MW, Chertow GM, Rennke HG, Gurnani A, Jiang T, Shahsafaei A, Troy JL, Brenner BM, Mackenzie HS. Am J Physiol Renal Physiol. 2001; 280 (2): F343-55
• Mortality and costs of acute renal failure associated with amphotericin B therapy. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R. Clin Infect Dis. 2001; 32 (5): 686-93
• Suspected iron dextran-related adverse drug events in hemodialysis patients. Fletes R, Lazarus JM, Gage J, Chertow GM. Am J Kidney Dis. 2001; 37 (4): 743-9
• Validation of questionnaires to estimate physical activity and functioning in end-stage renal disease. Johansen KL, Painter P, Kent-Braun JA, Ng AV, Carey S, Da Silva M, Chertow GM. Kidney Int. 2001; 59 (3): 1121-7
• beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Hou FF, Miyata T, Boyce J, Yuan Q, Chertow GM, Kay J, Schmidt AM, Owen WF. Kidney Int. 2001; 59 (3): 990-1002
• Acute renal failure with interstitial nephritis in a patient with AIDS. Mouratoff JG, Tokumoto J, Olson JL, Chertow GM. Am J Kidney Dis. 2000; 35 (3): 557-61
• Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Lewis J, Salem MM, Chertow GM, Weisberg LS, McGrew F, Marbury TC, Allgren RL. Am J Kidney Dis. 2000; 36 (4): 767-74
• Chronic renal confusion: insufficiency, failure, dysfunction, or disease. Hsu CY, Chertow GM. Am J Kidney Dis. 2000; 36 (2): 415-8
• Crystalloids versus colloids for resuscitation in shock. Waikar SS, Chertow GM. Curr Opin Nephrol Hypertens. 2000; 9 (5): 501-4
• Hyperparathyroidism and dialysis vintage. Chertow GM, Plone M, Dillon MA, Burke SK, Slatopolsky E. Clin Nephrol. 2000; 54 (4): 295-300
• Issues in renal nutrition for persons from the former Soviet Union. Gorodetskaya I, Matel J, Chertow GM. J Ren Nutr. 2000; 10 (2): 98-102
• Leveling the "paying" field in end-stage renal disease. Chertow GM, Am J Med. 2000; 108 (8): 666-8
• Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Nephrol Dial Transplant. 2000; 15 (4): 559
• Ochrobactrum anthropi bacteremia in a patient on hemodialysis. Chertow GM, Am J Kidney Dis. 2000; 35 (6): E30
• Physical activity levels in patients on hemodialysis and healthy sedentary controls. Johansen KL, Chertow GM, Ng AV, Mulligan K, Carey S, Schoenfeld PY, Kent-Braun JA. Kidney Int. 2000; 57 (6): 2564-70
• Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. Chertow GM, Ackert K, Lew NL, Lazarus JM, Lowrie EG. Kidney Int. 2000; 58 (6): 2512-7
• Predicting acute renal failure after coronary bypass surgery: cross-validation of two risk-stratification algorithms. Fortescue EB, Bates DW, Chertow GM. Kidney Int. 2000; 57 (6): 2594-602
• Renal nutrition in the new millennium. Chertow GM, J Ren Nutr. 2000; 10 (1): 1
• Reply from the authors Chertow GM, Kidney Int. 2000; 58 (3): 1358-9
• Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. Chertow GM, Dillon MA, Amin N, Burke SK. J Ren Nutr. 2000; 10 (3): 125-32
• Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Chertow GM, Normand SL, Silva LR, McNeil BJ. Am J Kidney Dis. 2000; 35 (6): 1044-51
• Vintage, nutritional status, and survival in hemodialysis patients. Chertow GM, Johansen KL, Lew N, Lazarus JM, Lowrie EG. Kidney Int. 2000; 57 (3): 1176-81
• Bioelectrical impedance methods in clinical research: a follow-up to the NIH Technology Assessment Conference. Ellis KJ, Bell SJ, Chertow GM, Chumlea WC, Knox TA, Kotler DP, Lukaski HC, Schoeller DA. Nutrition. 1999 Nov-Dec; 15 (11-12): 874-80
• Metabolic and monetary costs of avoidable parenteral nutrition use. Trujillo EB, Young LS, Chertow GM, Randall S, Clemons T, Jacobs DO, Robinson MK. JPEN J Parenter Enteral Nutr. 1999 Mar-Apr; 23 (2): 109-13
• A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E. Clin Nephrol. 1999; 51 (1): 18-26
• Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Weinfeld MS, Chertow GM, Stevenson LW. Am Heart J. 1999; 138 (2 Pt 1): 285-90
• Estimates of body composition as intermediate outcome variables: are DEXA and BIA ready for prime time? Chertow GM, J Ren Nutr. 1999; 9 (3): 138-41
• Evidence-based organ allocation. Zenios SA, Wein LM, Chertow GM. Am J Med. 1999; 107 (1): 52-61
• Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Chertow GM, Owen WF, Lazarus JM, Lew NL, Lowrie EG. Kidney Int. 1999; 56 (5): 1872-8
• Modality-specific nutrition support in ESRD: weighing the evidence. Chertow GM, Am J Kidney Dis. 1999; 33 (1): 193-7
• The urea [clearance x dialysis time] product (Kt) as an outcome-based measure of hemodialysis dose. Lowrie EG, Chertow GM, Lew NL, Lazarus JM, Owen WF. Kidney Int. 1999; 56 (2): 729-37
• Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. Hou FF, Boyce J, Chertow GM, Kay J, Owen WF. J Am Soc Nephrol. 1998; 9 (2): 277-83
• Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Owen WF, Hou FF, Stuart RO, Kay J, Boyce J, Chertow GM, Schmidt AM. Kidney Int. 1998; 53 (5): 1365-73
• Cancer screening and detection in patients with end-stage renal disease. Gornik HL, Lazarus JM, Chertow GM. Int J Artif Organs. 1998; 21 (9): 495-500
• Clearance of Pneumocystis carinii cysts in acute P carinii pneumonia: assessment by serial sputum induction. O'Donnell WJ, Pieciak W, Chertow GM, Sanabria J, Lahive KC. Chest. 1998; 114 (5): 1264-8
• Dialysis: cost-effective "SUPPORT" for patients with acute renal failure. Chertow GM, Am J Kidney Dis. 1998; 31 (3): 545-8; discussion 548-9
• Dose of hemodialysis and survival: differences by race and sex. Owen WF, Chertow GM, Lazarus JM, Lowrie EG. JAMA. 1998; 280 (20): 1764-8
• Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. Ginsburg ES, Walsh B, Greenberg L, Price D, Chertow GM, Owen WF. Kidney Int. 1998; 54 (4): 1344-50
• Haemobilia mimicking acute cholecystitis following percutaneous renal biopsy. Lee MC, Jacobs DO, Chertow GM. Nephrol Dial Transplant. 1998; 13 (8): 2118-20
• Independent association between acute renal failure and mortality following cardiac surgery. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Am J Med. 1998; 104 (4): 343-8
• Olecranon bursitis caused by infection with Candida lusitaniae. Behar SM, Chertow GM. J Rheumatol. 1998; 25 (3): 598-600
• Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. Chertow GM, Lazarus JM, Paganini EP, Allgren RL, Lafayette RA, Sayegh MH. J Am Soc Nephrol. 1998; 9 (4): 692-8
• A practical approach to acute renal failure. Mindell JA, Chertow GM. Med Clin North Am. 1997; 81 (3): 731-48
• Antigen-independent determinants of graft survival in living-related kidney transplantation. Chertow GM, Brenner BM, Mori M, MacKenzie HS, Milford EL. Kidney Int Suppl. 1997: 63 S84-6
• Bioimpedance norms for the hemodialysis population. Chertow GM, Lazarus JM, Lew NL, Ma L, Lowrie EG. Kidney Int. 1997; 52 (6): 1617-21
• Development of a population-specific regression equation to estimate total body water in hemodialysis patients. Chertow GM, Lazarus JM, Lew NL, Ma L, Lowrie EG. Kidney Int. 1997; 51 (5): 1578-82
• Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Hou FF, Chertow GM, Kay J, Boyce J, Lazarus JM, Braatz JA, Owen WF. Kidney Int. 1997; 51 (5): 1514-9
• Nephrology. Chertow GM, JAMA. 1997; 277 (23): 1872-3
• On the design and analysis of multicenter trials in acute renal failure. Chertow GM, Am J Kidney Dis. 1997; 30 (5 Suppl 4): S96-101
• Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E. Am J Kidney Dis. 1997; 29 (1): 66-71
• Poorer graft survival in African-American transplant recipients cannot be explained by HLA mismatching. Chertow GM, Milford EL. Adv Ren Replace Ther. 1997; 4 (1): 40-5
• Preoperative renal risk stratification. Chertow GM, Lazarus JM, Christiansen CL, Cook EF, Hammermeister KE, Grover F, Daley J. Circulation. 1997; 95 (4): 878-84
• Renal vasculitis with HIV seropositivity: potential manifestation of cytomegalovirus infection. Chertow GM, Rennke HG, Curhan GC, Brady HR. Am J Kidney Dis. 1997; 30 (3): 428-32
• The rise and fall of atrial natriuretic peptide for acute renal failure. Brenner RM, Chertow GM. Curr Opin Nephrol Hypertens. 1997; 6 (5): 474-6
• Grafts vs fistulas for hemodialysis patients: equal access for all? Chertow GM, JAMA. 1996 Oct 23-30; 276 (16): 1343-4
• "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Denton MD, Chertow GM, Brady HR. Kidney Int. 1996; 50 (1): 4-14
• Antigen-independent determinants of cadaveric kidney transplant failure. Chertow GM, Milford EL, Mackenzie HS, Brenner BM. JAMA. 1996; 276 (21): 1732-6
• Birth weight and adult hypertension and obesity in women. Curhan GC, Chertow GM, Willett WC, Spiegelman D, Colditz GA, Manson JE, Speizer FE, Stampfer MJ. Circulation. 1996; 94 (6): 1310-5
• Fanconi's syndrome and tubulointerstitial nephritis in association with L-lysine ingestion. Lo JC, Chertow GM, Rennke H, Seifter JL. Am J Kidney Dis. 1996; 28 (4): 614-7
• Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Am J Med. 1996; 101 (1): 49-53
• Performance characteristics of a dialysis-related amyloidosis questionnaire. Chertow GM, Trimbur T, Karlson EW, Lazarus JM, Kay J. J Am Soc Nephrol. 1996; 7 (8): 1235-40
• Restless legs syndrome in end-stage renal disease. Winkelman JW, Chertow GM, Lazarus JM. Am J Kidney Dis. 1996; 28 (3): 372-8
• Trimethoprim-sulfamethoxazole and hypouricemia. Chertow GM, Seifter JL, Christiansen CL, O'Donnell WJ. Clin Nephrol. 1996; 46 (3): 193-8